14 March 2019
Sofitel Legend Amsterdam The Grand
Panel – EU and US market review and outlook for 2018
Sam Fazeli, Senior Pharma Analyst and Head of EMEA at Bloomberg
Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI <GO>. Mr. Fazeli specializes in European pharmaceuticals and biotechnology.
Mr. Fazeli brings with him over 15 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC.
Prior to joining Bloomberg in 2010, Mr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, Mr. Fazeli was a research scientist for seven years.
Mr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.
Andrew McDonald, Founding Partner & CEO, LifeSci Advisors
Andrew McDonald is an experienced healthcare investment professional with expertise in identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci, Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Jacques Bouwens, Russell Reynolds Associates,
Jacques Bouwens leads the firm’s Global Healthcare sector. He specializes in senior-level executive and non-executive board assignments in the healthcare and technology industries.
Jacques has recently authored a broad range of articles covering leadership strategies. Recent assignments include advising clients on CEO succession and senior level executive assessments. Most recently Jacques has advised a number of large multinationals with respect to the appointment of experienced non-executive directors with specific relevant experience in healthcare.
Prior to joining Russell Reynolds Associates in 1995, Jacques served for five years as Director, Human Resources Europe for St. Jude Medical, a global medical technology and services company. At St. Jude, he was responsible for the creation of the company’s European organization, headquartered in Brussels with sales offices in 12 countries throughout Europe. Previously, he held a number of human resources positions at GE.
Jacques received his M.S. degree in social and organizational psychology from the State University of Utrecht, the Netherlands, and his M.S. degree in industrial psychology from the University of Hull.
Michael Schatzschneider, Managing Director Business Development Techhub Germany, Euronext
Michael, based in Frankfurt, is supporting German Tech companies and their stakeholder in the Euronext-IPO process. He has gained wide experience in corporate finance, in particular in ECM/DCM, M&A and in investment-research & valuation while working with BHF BANK and Commerzbank, among others. His sector expertise covers in particular TMT, Greentech and Healthcare. Michael was Head of Financial Markets at Kirch Gruppe in Munich and held interims-CFO positions in various German SMEs. He holds a University Diploma in Business Administration (Dipl. Kfm.) from Johann Wolfgang Goethe University in Frankfurt and is a Chartered European Financial Analyst (CEFA).
How to build a multi-billion $ biotech company in Europe; A conversation :
Jan van de Winkel CEO, Genmab
Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Biotech AG, member of the board of directors of Celdara Medical and LEO Pharma, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
Onno vd Stolpe CEO Galapagos
Onno van de Stolpe founded our company in 1999 and has served as our Chief Executive Officer and a member of our board of directors from 1999 to the present. From 1998 to 1999, he was the Managing Director of Genomics at IntroGene B.V. (later Crucell N.V., which was acquired by Johnson & Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe B.V. He established this European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in the Netherlands. Mr. Van de Stolpe started his career as Manager of Business Development at MOGEN International N.V. in Leiden. He received an MSc degree from Wageningen University. Mr. Van de Stolpe currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V.
Werner Lanthaler CEO Evotec
Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec on 06 March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.
Edwin Moses CEO of Ablynx
- Dr Edwin Moses has been Chairman of Ablynx from 2004 till 2013, and in 2006 he was appointed Chief Executive Officer of the Company.
- Previously: Amersham International, Raggio-Italgene, CEO and Chairman of Oxford Asymmetry International before the £316M merger with Evotec
- Extensive Board experience with more than 15 life science companies in Europe – 4 IPOs and multiple M&As